Monoclonal antibodies (MAbs) were raised against the transmembrane protein (TM) gp41 of human immunodeficiency virus type 1 (HIV-1, strain HTLV-IIIB). The reactivity of three TM-specific MAbs was investigated in several tests, ELISA, immunostaining of Western blots, immunofluorescence and an alkaline phosphatase-anti-alkaline phosphatase assay. Epitope mapping was done by using overlapping gp41 peptides produced as Escherichia coli fusion proteins and synthetic peptides. In an in vitro assay, all three MAbs showed enhancing effects on HIV-1 infection after single or repeated treatment with the purified MAbs at concentrations of 6 to 25 ~tg/ml. The enhancing domain is located between amino acids 724 and 752 of the env protein sequence. Homologous peptides based on this sequence were used for analysis of sera from 100 individuals at different stages of HIV infection to evaluate the relevance of antibodies against this region to the prognosis of disease. No antibodies reactive with this region were found in ELISA, indicating that this domain is not immunogenic in humans.
The transmembrane protein (TM) gp41 of human immunodeficiency virus (HIV) is derived by proteolytic processing of the env precursor gpl60 by cellular proteases (McCune et al., 1988) . The oligomeric gp41 forms the membrane anchor for the non-covalently linked surface glycoprotein (SU) gpl20, which functions as the virus receptor of CD4 ÷ cells (Pinter et al., 1989) . The fusion of the virus with the host cell membrane is mediated by TM (Freed et al., 1990) . Several regions of gp41 have been functionally defined either by their induction of antibodies or effect on membrane fusion (Gnann et al., 1987; Veronese et al., 1989; Hunt et al., 1990; Larcher et al., 1990; Chirmule et al., 1990; Helseth et al., 1990) . The immunodominant region (amino acids 598 to 609) has been described mainly by analysis using human monoclonal antibodies (MAbs) (Bugge et al., 1990; Teeuwsen et al., 1990; Oldstone et al., 1991 ; .
Three MAbs directed against gp41 of HIV-1 strain HTLV-IIIB were selected after fusion of SP2/0 cells with spleen cells of BALB/c mice immunized with recombinant gp41 fusion protein (pMB242; Fig. 1 ). The recombinant protein has previously been shown to be highly reactive with sera from HIV-l-infected individuals (Brfker et al., 1988) . MAbs specific for HIV-1 TM were identified by ELISA using whole HIV-1 and -2 as the antigen preparation (Table 1) ; minimal cross-reactivity with HIV-2 was observed. In immunoblots using purified virus the MAbs stained gp41 only very faintly, which indicates that the respective epitopes are not well preserved under denaturating conditions. In immunofluorescence assays of HIV-l-infected cells, two MAbs (88-158/022 and /079) produced distinct membraneassociated fluorescence on HIV-l-infected H9 syncytial cells. All three MAbs were reactive with HIV-l-infected H9 cells in an alkaline phosphatase-anti-alkaline phosphatase (APAAP) assay, showing their efficacy for immunohistological staining. The immunological characterization of the three MAbs is summarized in Table 1 .
The epitopes recognized by the MAbs were identified by immunoblot analysis using a panel of overlapping recombinant fusion proteins (Fig. 1) . As all three MAbs reacted with the fusion proteins encoded by pMB2440, pMB2440AHA, pMB242 and pMB261, but not with those encoded by pMB1790, pMB255 or pMB252, the binding site was deduced to be located within the 90 bp AvaI/BamHI fragment. To map the epitope more precisely, the gp41 DNA sequence between amino acids 732 and 758 was expressed as a fusion protein with flgalactosidase (fl-gal) from pMB379. The anti-gp41 MAbs reacted with this fusion protein and also with a synthetic peptide containing amino acids 724 to 752 ( et al., 1988) . All fusion proteins were tested for correct expression by using HIV-l-positive human sera. Only the recombinant fusion oligopeptide pMB379 gave no reaction. Cell extracts were separated by 10~ SDS-PAGE. The binding of antibodies was visualized by using alkaline phosphatase-conjugated rabbit anti-mouse IgG and the appropriate substrate, naphthol AS-MX phosphate (Sigma). The peptide (amino acids 724 to 752) was synthesized according to the cDNA sequence published by Rather et al. (1985) by methods described previously (Pelzer et al., 1991) . Numbering of the amino acid sequence is taken from the Los Alamos database (Myers et al., 1988 The epitope defined maps to a highly conserved region which is postulated to be an extracellular domain of gp41 (Modrow et al., 1987; Starcich et al., 1986) . In this region B cell epitopes with neutralizing as well as immunosuppressive effects have been described . This might be one reason why we could not raise antibodies in rabbits against a peptide consisting of amino acids 724 to 752 coupled to keyhole limpet haemocyanin to test the enhancing effects of polyclonal antisera. Analysis of sera from approximately 100 individuals at different stages of HIV infection for antibodies directed against this region showed no significant reaction, demonstrating that this region is not immunogenic in humans.
MAbs were analysed for antiviral activity in an in vitro infection assay. HIV-l-infected CD4 ÷ Jurkat cells were mixed with uninfected cells at a ratio of 1 : 10 and seeded in 96-well microtitre plates. Four wells in parallel were treated only on day 0, and four other wells were also treated on days 4, 7 and 11 with various concentrations (6 to 100 ~tl/ml) of purified anti-gp41 MAbs. Cultures were monitored microscopically and by analysis of reverse transcriptase (RT) activity in cell culture supernatants (Gregersen et al., 1988) . The RT activity was calculated as a percentage of the activity of the untreated control cell culture (Fig. 2) . Depending on the MAb concentration, we observed two different effects. At higher concentrations (50 to 100 ~tl/ml) there was a decrease in RT activity to 50 ~ compared to the control, indicating a slight inhibitory effect of the antibodies on virus growth or release into the supernatant. However, at lower MAb concentrations (6 to 25 ~tl/ml) there was a remarkable increase in RT activity up to 280~. This was accompanied by extensive syncytium formation as early as 2 days post-infection. This enhancing effect was never seen in analogous experiments using other anti-HIV HIV-I (strain BH10) grown in KE37 cells and HIV-2 (strain ROD) grown in CEM cells were purified by centrifugation through a 10 ~ sucrose cushion. Partially purified virus (5 to 10 ~tg; 100 ktl/well) was coated onto 96-well microtitre plates (Nunc). The reactions were visualized by using rabbit anti-mouse conjugated peroxidase and the substrate H2Oz-TMB. Background reactivity was 0-04 + 0.01.
t" Immunofluorescence studies were performed on KE37 cells infected with HIV-1 or -2. Cells were spotted onto slides, air-dried and fixed overnight in acetone : methanol 1 : 1 (v/v). IgG was purified from hybridoma culture supernatants by Protein A affinity chromatography. The detecting antibody was fluorescein-conjugated goat anti-mouse Fc antibody (Dianova). Uninfected cells were used as a control.
HIV 1-infected cells were attached to slides using a Shandon Cytospin. Cells were fixed with acetone: methanol (1 : 1 v/v) for 6 h at 4 °C. As the second antibody, alkaline phosphatase-conjugated rabbit anti-mouse IgG (1:40; Dianova) was used followed by the preformed APAAP complex (1:50; Dianova). Uninfected cells served as a control. Method according to Cordell et al. (1984) .
§ Mouse IgG, subclasses were determined by the Ouchterlony technique. and 88-158/079 (c). Hybridoma culture supernatant purified by Protein A affinity chromatography was used. RT activity is shown as a percentage of that of an untreated HIV-1-infected control. RT activity was determined in the supernatant by a microscale assay (Gregersen et al., 1988) . The c.p.m, in the positive control reached a maximum of 10916 with an S.D. of 932 after 7 days. The supernatant of uninfected cells served as a control and reached an average of 847 c.p.m, with an S.D. of 147. Results greater than twice the background were considered positive. The arrows indicate the times when MAbs were added. ©, 6 ~tg/ml; A, 12-5 Ixg/ml; V, 25 p.g/ml;O, 50 ~tg/ml; II, 100 ~tg/ml MAb.
MAbs, i.e. anti-pl7, anti-p24 or anti-gpl20 (data not shown).
Finally, the TM-specific MAbs were directly tested for binding to the virion by pre-embedding immunoelectron microscopy (Gelderblom et al., 1987) . Using indirect immunoferritin labelling, two of the MAbs, 88-158/02 and -022, showed significant reactivity with the virus envelope (Fig. 3) , and MAb 88-158/079 (not shown) was weakly reactive.
TM has been described previously as a target for antibodies with enhancing activity (Robinson et al., 1990a (Robinson et al., , b, 1991 , but the relevant epitopes were different from that described here. From our results it may be concluded that the newly defined epitope is located outside the virus membrane and thus would be available for anti-gp41 MAbs. The enhancing effects ,may result either from attachment to free virus and stabilization of the glycoprotein complex, or by stimulation of virus-cell 
